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This work was supported by grants from the AIRC (Associazione Italiana per la Ricerca sul Cancro) to AN (IG10136 and IG16722) and by a grant from ABREOC 2016 to BG Multiple myeloma (MM) is a clinically and genetically heterogeneous malignant proliferation of plasma cells (PCs) with a typical multifocal distribution in the bone marrow (BM) and occasional extra-medullary dissemination. 1 Advances in the genetic knowledge of MM are increasingly translated into biomarkers to refine diagnosis, prognostication and treatment of patients. 2 MM genotyping has so far relied on the analysis of purified PCs from the bone marrow (BM) aspirate, which may fail in capturing the postulated spatial heterogeneity of the disease and imposes technical hurdles limiting its transfer in the routine and clinical grade diagnostic laboratory. In addition, longitudinal monitoring of disease molecular markers may be limited by patient discomfort caused by repeated BM samplings during disease course. Circulating tumor DNA is shed into the peripheral blood (PB) by tumor cells and can be used as source of tumor DNA for the identification of cancer-gene somatic mutations, with obvious advantages in terms of accessibility. In addition, the systemic origin of cell-free DNA (cfDNA) allows catching the entire tumor heterogeneity. 3 Tumor cfDNA was identified in MM patients by preliminary studies tracking the clonotypic V(D)J rearrangement as disease fingerprint, 4 or genotyping a highly restricted set of cancer genes that were not specifically addressed to resolve the typical MM mutational landscape. [5] [6] [7] We developed a CAPP-seq ultra-deep targeted next-generation sequencing (NGS) approach to genotype a gene panel specifically designed to maximize the mutation recovery in plasma cell tumors, and compared the mutational profiling of cfDNA and tumor genomic DNA (gDNA) of purified PCs from BM aspirates in a consecutive series of patients representative of different clinical stages of PC tumors ranging from monoclonal gammopathy of undetermined significance (MGUS), to smoldering MM, and symptomatic MM.
The study was based on a series of 28 patients with PC disorders, whose clinical and molecular characteristics were consistent with an unselected cohort of PC dyscrasia patients ( Supplementary Table   S1 ) [ : 31 kb: BRAF, CCND1, CYLD,   DIS3, EGR1, FAM46C, IRF4, KRAS, NRAS, PRDM1, SP140, TP53, TRAF3, ZNF462 ; Supplementary Table   S2 ) was specifically designed and optimized to allow a priori the recovery of at least one mutation in 68% (95% confidence interval: 58-76%) of patients, based on literature data. [8] [9] [10] Ultra-deep NGS was performed on MiSeq (Illumina) using the CAPP-seq library preparation strategy (NimbleGen). 11 The somatic function of VarScan2 was used to call non-synonymous somatic mutations, and a stringent bioinformatic pipeline was developed and applied to filter out sequencing errors (detection limit 3x10 -3 Figure S2 and Supplementary Table S3 ). Overall, within the interrogated genes, 18/28 (64%) patients had at least one non-synonymous somatic mutation detectable in cfDNA ( Figure 1A and Table 1A ); 28 total variants were identified, with a range of 1-4 mutations per patient. Quite consistent with the typical spectrum of mutated genes in MM, plasma cfDNA genotyping revealed somatic variants of NRAS in 25%; KRAS in 14%; TP53, TRAF3 and FAM46C in 11%, respectively, CYLD and DIS3 in 7%, respectively, and BRAF and IRF4 in 4% of cases, respectively. Variants in NRAS, KRAS and BRAF genes occurred in a mutually exclusive manner, and they overall involved 43% of patients. TP53 mutations were positively associated with the deletion of the remaining allele as revealed by fluorescence in situ hybridization on purified PCs (P=0.02, Fisher-exact test). Overall, the molecular spectrum of mutations discovered in tumor cfDNA reflected previous observations in genomic studies based on PC genotyping (see representative example for the two most frequently mutated genes in Supplementary Figure S3 ), thus supporting the tumor origin of the mutations identified in cfDNA.
To validate the tumor origin of mutations discovered in cfDNA and to derive the accuracy of our approach in resolving tumor genetics, the genotype of cfDNA was matched with that of gDNA from purified BM PCs in all the patients. Sequencing of tumor gDNA identified 39 somatic mutations in 20/28 (71.4%) patients ( Figure 1A ). cfDNA genotyping correctly identified 72% of mutations (n=28/39) that were discovered in tumor PCs (Supplementary Figure S4A) ; overall the variant allele frequencies in plasma samples correlated with those in tumor biopsies (Pearson correlation coefficient=0.58, P=9.6e-05; Supplementary Figure S4B ) and with the degree of bone marrow involvement (Pearson correlation coefficient=0.5, P=0.006). Specifically, of the 28 mutations correctly identified in tumor cfDNA, four were detected in two SMM patients out of a total of 7 biopsy-confirmed mutations (4/7, 57%) in three SMM patients, and 24 were detected in 16 MM cases out of a total of 32 biopsy-confirmed mutations (24/32, 75%) in 17 MM cases.
Notably, BM PC confirmed mutations not discovered in cfDNA (n=11) had a low representation in the tumor (median allelic frequency: 2.5%; range: 1.1-4.96%) (Table 1B, Figure 1B ). Since circulating tumor DNA is diluted in cfDNA from normal cells, 12, 13 variants that are already rare in tumor gDNA are much less represented in plasma and may fall below the sensitivity threshold of the CAPP-seq under the experimental conditions adopted in this work. Consistently, based on ROC analysis, cfDNA genotyping has the best performance in detecting tumor PC confirmed mutations when they are represented in at least 5% of the alleles of tumor plasma cells (Supplementary Figure S4C ). Above this threshold, cfDNA genotyping detected 100% of biopsy-confirmed mutations. Noteworthy, cfDNA genotyping was still able to detect almost half (10/21) of low-abundance mutations in tumor PC (i.e. allelic frequency <20%), indicating a good capacity of tumor cfDNA to mirror also the subclonal composition of the tumor. Of course, these data concerning the sensitivity of cfDNA genotyping refer to the depth of coverage used in the paper, and higher depth may allow a better overlap of gDNA and cfDNA. In none of the cases cfDNA genotyping identified additional somatic mutations not detected in the purified BM PCs, thus suggesting that, as far as our limited patient cohort is concerned, the genotype of PC collected from a single tumor site is already representative of the entire tumor genetics. Alternatively, spatial genomic heterogeneity, supported by very recent findings in MM, 14 may exist but involving minor subclones not sufficiently represented to be detectable in plasma.
Our results provide the proof of principle that circulating tumor cfDNA genotyping is a feasible, noninvasive, real-time approach that reliably detects clonal and subclonal somatic mutations represented in at least 5% of alleles in tumor PCs. Despite the genetic heterogeneity characterizing MM, and the inclusion in the study cohort of seven patients at pre-malignant/asymptomatic disease stages, the designed gene-panel employed in our study proved to be very effective, in that it allowed the recovery of at least one mutation in tumor gDNA of 20/28 (71%) cases. To the best of our knowledge, this is the first gene panel specifically created to maximize mutational recovery in MM patients by using an affordable number of genes, and by virtue of this potentially effective and manageable even in clinical practice in a hopefully near future.
One of the original findings of the study is that cfDNA genotyping can resolve tumor genetics also in cases at early disease stages as SMM patients, who may benefit the most from this non-invasive approach.
Indeed, among asymptomatic patients cfDNA genotyping could allow a non-invasive longitudinal molecular monitoring of clonal evolution and the identification of the switch point on which the disease acquires highrisk genetic features. This has been prevented so far by the unfeasibility of serial BM sampling in the clinical routine.
An immediate clinical application of cfDNA genotyping in MM could be the incorporation of this minimally-invasive method in clinical trials for the identification of patients carrying actionable mutations and their longitudinal genetic monitoring during targeted therapy administration or for the estimation of minimal residual disease. 
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Supplementary Figure S5 Table S1 ). The following biological material was collected: (1) gDNA extraction PB granulocytes were separated by Ficoll gradient density centrifugation as a source of normal germline gDNA. Tumor gDNA was isolated from PCs purified using CD138 immunomagnetic microbeads as previously described 1, 2 (CD138+ cell percentage was ≥90% in all cases). gDNA was extracted according to standard procedures.
Library design for hybrid selection
A targeted resequencing gene panel, including coding exons and splice sites of 14 genes that are recurrently mutated in MM patients, was specifically designed for this project (target region: 30989bp: BRAF, CCND1, CYLD, DIS3, EGR1, FAM46C, IRF4, KRAS, NRAS, PRDM1, SP140, TP53, TRAF3, ZNF462; Supplementary Table S2 ). Inclusion criteria of gene panel design were based on publicly available sequencing data from three distinct datasets [3] [4] [5] and were as follows:
(i) genes that were recurrently mutated in ≥ 3% of MM tumors; (ii) genes that were cross-validated in at least two of the considered genomic datasets. An in silico validation of the designed gene panel in the three aforementioned patients cohorts resulted in the recovery of at least one clonal mutation in 68% (95% confidence interval [CI]: 58 to 76) of MM cases.
CAPP-seq library preparation and ultra-deep NGS
The gene panel was analyzed in plasma cfDNA, and for comparative purposes to filter out polymorphisms, in normal gDNA from the paired granulocytes as source of germline material. The gDNA from the paired CD138+ purified plasma cells from BM aspiration was also investigated in the same cases to assess the accuracy of plasma cfDNA genotyping. Tumor and germline gDNA (median 400 ng) were sheared through sonication before library construction to obtain 200-bp fragments.
Plasma cfDNA, which is naturally fragmented, was used (average: 59 ng; median: 48 ng; range: 0.05-400 ng) for library construction without additional fragmentation. Targeted ultra-deep-next generation sequencing was performed on plasma cfDNA, tumor and germline gDNA by using the CAPP-seq approach, which has been validated for plasma cfDNA genotyping 6 . The NGS libraries were constructed using the KAPA Library Preparation Kit (Kapa Biosystems) and hybrid selection was performed with the custom SeqCap EZ Choice Library (Roche NimbleGen). The manufacturer's protocols were modified as previously reported 6 . Multiplexed libraries were sequenced using 300-bp paired-end runs on an Illumina MiSeq sequencer.
Each run included 24 multiplexed samples in order to allow >2000x coverage in >80% of the target region.
Bioinformatic pipeline for variant calling
Mutation calling in plasma cfDNA was performed separately and in blind from mutation calling in tumor gDNA from purified PCs. We deduped FASTQ sequencing reads by utilizing FastUniq v1. Figure S5 for a representative example).
Statistical analysis
The sensitivity and specificity of plasma cfDNA genotyping were calculated in comparison with tumor gDNA genotyping as the gold standard. The analysis were performed with the Statistical Package for the Social Sciences (SPSS) software (Chicago, IL) and with R statistical package (http://www.r-project.org). 
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